Aripiprazole Safety During Pregnancy and Breastfeeding
Aripiprazole can be continued during pregnancy when clinically necessary, but should be avoided or discontinued during breastfeeding due to high rates of lactation failure.
Pregnancy Safety
The available evidence suggests aripiprazole use during pregnancy carries acceptable risks when the medication is essential for maternal functioning. The FDA label states that published data from observational studies, birth registries, and case reports do not report a clear association between atypical antipsychotics and major birth defects 1. However, the label also notes "it is not known if aripiprazole tablets will harm your unborn baby" 1.
Key Pregnancy Considerations:
- No clear teratogenic signal: Large database studies and prospective data show no consistent evidence of increased major malformations 2
- Neonatal complications possible: Late pregnancy exposure may worsen neonatal outcomes, including poor neonatal adaptation 3
- Pregnancy registry available: Women should be encouraged to register with the National Pregnancy Registry for Atypical Antipsychotics (1-866-961-2388) 1
Clinical Management During Pregnancy:
- Continue aripiprazole if required for daily functioning and maternal mental health stability
- Monitor plasma levels throughout pregnancy, as they decline compared to pre-pregnancy levels—dosage increases may be needed to maintain therapeutic effect 3
- Consider withdrawing the drug before the last month of pregnancy to reduce neonatal complications, but only if maternal stability allows 3
- Ensure delivery occurs in a hospital with neonatal intensive care capabilities 3
- Monitor fetal growth, maternal blood pressure, and appropriate weight gain throughout pregnancy
Breastfeeding Safety
Aripiprazole should be avoided during breastfeeding due to its prolactin-lowering mechanism causing high rates of lactation failure.
Critical Breastfeeding Evidence:
The most recent and compelling evidence comes from a 2025 Indian perinatal psychiatry study showing that 74% of women (26/35) experienced complete lactation failure and 11% had insufficient milk production while taking aripiprazole 4. This finding is corroborated by a 2025 Australian multi-site study where 73.5% of mothers ceased breastfeeding by their last midwife appointment, with only one mother able to exclusively breastfeed 5.
Mechanism and Dose Relationship:
- Aripiprazole is a partial dopamine agonist that lowers prolactin levels, directly suppressing lactation 5
- The effect appears dose-related, with higher doses associated with greater lactation suppression 5
- The FDA label confirms "aripiprazole passes into your breast milk" and notes "reports of inadequate milk supply in lactating women taking aripiprazole" 1
Clinical Recommendations for Breastfeeding:
Discontinue aripiprazole before delivery if possible to allow for successful breastfeeding. If maternal psychiatric stability absolutely requires continuation:
- Counsel extensively about the very high likelihood (>70%) of lactation failure
- Prepare for formula feeding as the primary feeding method
- Monitor infant weight gain closely if any breastfeeding is attempted
- Consider the lowest effective dose to potentially reduce lactation suppression
- The relative infant dose ranges from 0.7% to 8.3% of maternal weight-adjusted dosage 1, but the primary concern is maternal milk production failure, not infant toxicity
Common Pitfalls to Avoid:
- Do not assume aripiprazole is "breastfeeding-compatible" simply because it's an atypical antipsychotic—its unique mechanism causes lactation failure
- Do not wait until after delivery to discuss lactation issues—counsel during pregnancy so mothers can make informed feeding plans
- Do not abruptly discontinue during pregnancy without psychiatric consultation if the medication is controlling severe symptoms
- Do not overlook neonatal monitoring if used in late pregnancy—ensure appropriate neonatal care is available
The evidence strongly supports that while pregnancy exposure appears relatively safe when necessary for maternal health, the lactation data is unequivocal: aripiprazole causes lactation failure in the majority of women and should be avoided during breastfeeding 4, 5.